Lutfi H. Alfarsi
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
Alfarsi, Lutfi H.; El Ansari, Rokaya; Craze, Madeleine L.; Masisi, Brendah K.; Ellis, Ian O.; Rakha, Emad A.; Green, Andrew R.
Rokaya El Ansari
Madeleine L. Craze
Brendah K. Masisi
Professor IAN ELLIS IAN.ELLIS@NOTTINGHAM.AC.UK
Professor of Cancer Pathology
EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
ANDREW GREEN email@example.com
PPFIA1 is an important regulator of cell migration and invasion, regulating focal adhesion signalling and disassembly. PPFIA1 is frequently amplified in breast cancer, and recent functional studies indicate that PPFIA1 is an important promoter of migration and invasion in breast cancer. This study aims to evaluate the utility of PPFIA1 expression in the luminal breast cancer as a prognostic marker to predict the response to endocrine therapy.
Large, well-characterised cohorts of primary luminal breast cancer patients with long-term follow-up was assessed for the clinical impact of PPFIA1 expression at the transcriptomic and proteomic levels. Prognostic significance of PPFIA1 and its relationship with clinical outcome and benefit of endocrine therapy were analysed. In addition, its association with other related-genes was analysed.
There was significant association between PPFIA1 expression and a member of the liprin family that involves in cell invasion (PPFIBPI), and the cell cycle regulator (CCND1), whereas a negative association was observed with the tumour suppressor gene (CD82). Patients with high PPFIA1 expression were associated with high risk of recurrence, distant metastasis and death from breast cancer (P< 0.05). Importantly, high PPFIA1 expression predicted relapse in a subset of patients who were subject to endocrine treatment alone, and was an independent prognostic marker of unfavourable outcome in these patients (P< 0.05).
These findings support the proposed role for PPFIA1 as a regulator of cell migration in breast cancer and provides definitive evidence for the clinical utility of PPFIA1 expression in patients with luminal breast cancer. Most importantly, our data suggests that PPFIA1 might be a potential predictive marker for poor benefit from endocrine therapy.
|Journal Article Type||Article|
|Publication Date||May 14, 2020|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Alfarsi, L. H., El Ansari, R., Craze, M. L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer, 20(1), https://doi.org/10.1186/s12885-020-06939-6|
|Keywords||Breast cancer, oestrogen receptor, Endocrine resistance, PPFIA1, Liprin, Predictive biomarker, Genetics, Cancer Research, Oncology|
|Additional Information||Received: 24 February 2020; Accepted: 7 May 2020; First Online: 14 May 2020; : This study was performed according to the REMARK guidelines for tumour prognostic studies [CitationRef removed], and approved by the Nottingham Research Ethics Committee 2 under the title “Development of a molecular genetic classification of breast cancer”. All samples from Nottingham used in this study were pseudo-anonymised and collected prior to 2006 and therefore under the Human Tissue Act informed patient consent was not needed. Release of data was also pseudo-anonymised as per Human Tissue Act regulations.; : Not applicable.; : The authors declare that they have no competing interests.|
RESEARCH ARTICLEOpen AccessPPFIA1 expression associates with poorresponse to endocrine treatment in luminalbreast cancer
You might also like
Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer
The Role Of Glutaminase In Cancer
Glutamate dehydrogenase (GLUD1) expression in breast cancer